[go: up one dir, main page]

MX2020014296A - Variantes de interleucina-2 y sus métodos de uso. - Google Patents

Variantes de interleucina-2 y sus métodos de uso.

Info

Publication number
MX2020014296A
MX2020014296A MX2020014296A MX2020014296A MX2020014296A MX 2020014296 A MX2020014296 A MX 2020014296A MX 2020014296 A MX2020014296 A MX 2020014296A MX 2020014296 A MX2020014296 A MX 2020014296A MX 2020014296 A MX2020014296 A MX 2020014296A
Authority
MX
Mexico
Prior art keywords
cells
relates
present
pharmaceutical compositions
polypeptides
Prior art date
Application number
MX2020014296A
Other languages
English (en)
Inventor
Yue- Sheng LI
Lingyun Rui
Jing Xu
Original Assignee
Cugene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cugene Inc filed Critical Cugene Inc
Publication of MX2020014296A publication Critical patent/MX2020014296A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a polipéptidos que comparten la secuencia primaria con IL-2 humana, excepto por varios aminoácidos que se han mutado. Un panel de variantes de IL-2 comprende mutaciones con una capacidad de elaboración impresionante que promueve preferentemente la proliferación, supervivencia, activación y/o función de las células T reguladoras inmunosupresoras (Treg: CD4+CD25+F0xP3+) sobre las células T efectoras y las células NK. También incluye los usos terapéuticos de dicho agente selectivo de IL-2, utilizado solo o en combinación con agentes inmunomoduladores o anticuerpos, proteínas o péptidos dirigidos al tejido de la enfermedad para tratar la deficiencia de células Treg, diversos trastornos autoinmunes e inflamatorios, trasplante de órganos y la enfermedad de injerto contra huésped. En otro aspecto, la presente invención se refiere a composiciones farmacéuticas que comprenden los polipéptidos descritos. Finalmente, la presente invención se refiere al uso terapéutico de los polipéptidos y composiciones farmacéuticas descritos debido a su efecto modulador selectivo del sistema inmune sobre enfermedades tal como trastornos autoinmunes e inflamatorios.
MX2020014296A 2018-06-22 2019-06-20 Variantes de interleucina-2 y sus métodos de uso. MX2020014296A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862689055P 2018-06-22 2018-06-22
US201862755016P 2018-11-02 2018-11-02
PCT/US2019/038248 WO2019246404A1 (en) 2018-06-22 2019-06-20 Interleukin-2 variants and methods of uses thereof

Publications (1)

Publication Number Publication Date
MX2020014296A true MX2020014296A (es) 2021-08-05

Family

ID=68984319

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020014296A MX2020014296A (es) 2018-06-22 2019-06-20 Variantes de interleucina-2 y sus métodos de uso.
MX2025006123A MX2025006123A (es) 2018-06-22 2020-12-18 Variantes de interleucina-2 y sus métodos de uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025006123A MX2025006123A (es) 2018-06-22 2020-12-18 Variantes de interleucina-2 y sus métodos de uso.

Country Status (9)

Country Link
US (3) US20210269497A1 (es)
EP (1) EP3810185A4 (es)
JP (2) JP7637415B2 (es)
KR (2) KR102873899B1 (es)
CN (2) CN112638406B (es)
AU (2) AU2019288496B2 (es)
CA (1) CA3102829A1 (es)
MX (2) MX2020014296A (es)
WO (1) WO2019246404A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7512210B2 (ja) 2018-09-21 2024-07-08 イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド 新規インターロイキン２およびその使用
US20220170028A1 (en) * 2019-06-14 2022-06-02 Cugene Inc Novel interleukin-2 variants and bifunctional fusion molecules thereof
CN120795117A (zh) * 2019-06-14 2025-10-17 科优基因公司 用于癌症治疗的新型白介素-2变体
EP4087865A2 (en) * 2020-01-10 2022-11-16 Bright Peak Therapeutics AG Modified il-2 polypeptides and uses thereof
US20230210951A1 (en) * 2020-01-14 2023-07-06 Synthekine, Inc. Il2 muteins
MX2022008771A (es) * 2020-01-14 2022-10-07 Synthekine Inc Metodos y composiciones de muteinas de il2 sesgadas.
CN115698052A (zh) * 2020-03-19 2023-02-03 信达生物制药(苏州)有限公司 白介素2突变体及其用途
CN118271419A (zh) 2020-03-31 2024-07-02 韩美药品株式会社 新型免疫刺激il-2类似物
MX2022016532A (es) * 2020-07-02 2023-04-12 Inhibrx Inc Polipeptidos que comprenden polipeptidos de il-2 modificados y usos de los mismos.
KR20230048151A (ko) * 2020-08-18 2023-04-10 유니버시타트 취리히 Cd25 편향된 항-il-2 항체
WO2022087458A1 (en) 2020-10-23 2022-04-28 Asher Biotherapeutics, Inc. Fusions with cd8 antigen binding molecules for modulating immune cell function
CN116806225A (zh) * 2020-12-23 2023-09-26 默沙东有限责任公司 用于治疗自身免疫性和炎性疾病的il-2突变蛋白
CA3215204A1 (en) * 2021-04-16 2022-10-20 Orionis Biosciences, Inc. Il-2 based constructs
GB2638094A (en) 2021-05-19 2025-08-13 Asher Biotherapeutics Inc Il-21 Polypeptides And Targeted Constructs
EP4366779A1 (en) 2021-07-09 2024-05-15 Bright Peak Therapeutics AG Modified tnf-antibodies and uses thereof
US20250215452A1 (en) 2022-03-25 2025-07-03 Universität Zürich Adenoviral Mediated Targeting of Activated Immune Cells
WO2023241653A1 (zh) * 2022-06-17 2023-12-21 舒泰神（北京）生物制药股份有限公司 白介素-2(il-2)突变体及其用途
CN116041539B (zh) * 2022-10-31 2023-07-21 山东博安生物技术股份有限公司 Il-2突变体免疫缀合物
KR20250133750A (ko) 2023-01-09 2025-09-08 오디세이 테라퓨틱스, 인코포레이티드 항-tnfr2 항원-결합 단백질 및 그의 용도
EP4689123A1 (en) * 2023-03-29 2026-02-11 WuXi Biologics Ireland Limited Il-2 variants with improved stability and compositions thereof
WO2025040797A1 (en) * 2023-08-23 2025-02-27 Depth Charge Ltd Interleukin-2 variant proteins that facilitate covalent chemical conjugation and uses thereof
KR20250126198A (ko) 2024-02-15 2025-08-25 한림대학교 산학협력단 인슐린 저항성의 예방 또는 치료를 위한 약학적 조성물
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
US20260028384A1 (en) 2024-04-17 2026-01-29 Visterra, Inc. Use of il-2 variant for treating kidney transplant rejection
WO2026006809A1 (en) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Multispecific molecules binding tnfr2 and cd25 and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
WO1990014363A1 (en) 1989-05-19 1990-11-29 Amgen Inc. Metalloproteinase inhibitor
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
TW371312B (en) 1995-04-12 1999-10-01 Chisso Corp Fluorine-substituted liquid-crystal compound, liquid-crystal composition and liquid-crystal display device
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US7531325B2 (en) 1997-04-25 2009-05-12 Sembiosys Genetics Inc. Method for cleavage of fusion proteins
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
MX353234B (es) 1999-01-15 2018-01-08 Genentech Inc Variantes de polipeptidos con función efectora alterada.
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
WO2003015697A2 (en) 2001-08-13 2003-02-27 University Of Southern California Interleukin-2 mutants with reduced toxicity
BR0214650A (pt) * 2001-12-04 2005-05-03 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
JP2007527242A (ja) * 2004-03-05 2007-09-27 カイロン コーポレーション 治療剤の患者耐容性を予測するためのインビトロ試験システム
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US20100098730A1 (en) 2008-10-14 2010-04-22 Lowman Henry B Immunoglobulin variants and uses thereof
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
WO2015118016A1 (en) 2014-02-06 2015-08-13 F. Hoffmann-La Roche Ag Interleukin-2 fusion proteins and uses thereof
CN106659757B (zh) * 2014-04-24 2022-01-28 利兰斯坦福初级大学董事会 白介素2的超级激动剂、部分激动剂和拮抗剂
EA038361B1 (ru) 2014-07-21 2021-08-13 Делиниа, Инк. Молекулы, которые избирательно активируют регуляторные t-клетки, для лечения аутоиммунных заболеваний
SI3283097T1 (sl) 2015-04-17 2020-06-30 Ferring B.V. FSH za zdravljenje neplodnosti
EP3280725B1 (en) * 2016-05-04 2020-08-26 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
JP7206190B2 (ja) * 2016-06-22 2023-01-17 ダヴィド・クラッツマン 遺伝的に修飾されたｔリンパ球
JP2019532996A (ja) * 2016-11-08 2019-11-14 デリニア，インコーポレーテッド 自己免疫疾患を処置するためのｉｌ−２変異体
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
CN111655718B (zh) 2017-12-19 2025-07-22 Xencor股份有限公司 经过工程化的il-2 fc融合蛋白

Also Published As

Publication number Publication date
AU2019288496A1 (en) 2021-01-14
MX2025006123A (es) 2025-07-01
CN120349426A (zh) 2025-07-22
EP3810185A4 (en) 2022-03-23
WO2019246404A1 (en) 2019-12-26
AU2025201170A1 (en) 2025-03-13
US20240254185A1 (en) 2024-08-01
JP7637415B2 (ja) 2025-02-28
JP2021528105A (ja) 2021-10-21
JP2024122980A (ja) 2024-09-10
CN112638406B (zh) 2025-04-22
KR20250156190A (ko) 2025-10-31
KR20210033995A (ko) 2021-03-29
CN112638406A (zh) 2021-04-09
US12152060B2 (en) 2024-11-26
CA3102829A1 (en) 2019-12-26
KR102873899B1 (ko) 2025-10-20
US20210269497A1 (en) 2021-09-02
US20240059751A1 (en) 2024-02-22
AU2019288496B2 (en) 2024-11-21
EP3810185A1 (en) 2021-04-28

Similar Documents

Publication Publication Date Title
MX2020014296A (es) Variantes de interleucina-2 y sus métodos de uso.
EA201991692A1 (ru) Иммуносконструированные плюрипотентные клетки
CO2019013001A2 (es) Proteínas de anticuerpo injertadas con citocina y métodos de uso en el tratamiento del cáncer
MX2021000607A (es) Células t con receptor de antígeno quimérico derivadas de células madre pluripotentes inmunomodificadas.
AR083858A1 (es) Polipeptidos derivados de la il-2 con actividad agonista para la terapia del cancer e infecciones cronicas
AR071756A1 (es) Agente para el tratamiento y/o la prevencion de una enfermedad autoinmune y para la formacion de celulas t reguladoras. procedimientos.
MX2021015834A (es) Nuevas variantes de interleucina-2 para el tratamiento de cancer.
UA130113C2 (uk) Мутеїн інтерлейкіну-21
CR20180174A (es) Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer
CR20180027A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer.
CU23734A1 (es) Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
CR20180460A (es) Tratamiento contra el cáncer de útero
CR20170419A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer.
MX355074B (es) Inmunoterapia novedosa contra varios tumores incluidos el cancer gastrico y gastrointestinal.
AR100225A2 (es) Anticuerpos anti-factor d humanizados y usos de los mismos
MX2022002193A (es) Nuevos peptidos y estructuras de soporte para el uso en la inmunoterapia contra el carcinoma epidermoide de cabeza y cuello y otros tipos de cancer.
CU20110096A7 (es) Compuestos que expanden las células madre hematopoyéticas
MX2022001319A (es) Peptidos novedosos, combinacion de peptidos y soportes para usarse en el tratamiento inmunoterapeutico de varios tipos de cancer.
PE20210316A1 (es) Inmunoterapia con peptidos restringidos a b 07 y una combinacion de peptidos contra el cancer y metodos relacionados
EA202192555A1 (ru) Комбинированная терапия для лечения рака
BR112019017393A8 (pt) Composição farmacêutica de evolocumab e seu uso, kit, método para preparar polipeptídeo de ligação a pcsk9 e método para formular polipeptídeo terapêutico
MX2020005235A (es) Celula humana transformada y uso de la misma.
MX2022003039A (es) Metodo de seleccion de donantes universales para identificar donantes de celulas nk.
PE20200746A1 (es) AGENTES DE iARN PARA LA INHIBICION DE LA EXPRESION DE ALFA-ENAC Y METODOS DE USO
CO2020006855A2 (es) Composiciones y métodos para el agotamiento de células cd2+